Suchergebnisse

A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

Langley, R.G; Toth, D; Russell, C.B; Li, J; Papp, K.A; Blauvelt, A; Gottlieb, A.B; Krueger, J.G; Milmont, C.E; Bolduc, C; Reich, K; Thaçi, D; Kricorian, G; Nirula, A; Paul, C; Cather, J; Baran, W; Klekotka, P.A

08-01-2016

Journal Article

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

Papp, K.A; Gooderham, M; Ports, W.C; Raman, M; Papacharalambous, J; Bissonnette, R; Poulin, Y; Mallbris, L; Purohit, V; Mamolo, C; Wang, C

11-01-2016

Journal Article

A systematic review of worldwide incidence of nonmelanoma skin cancer

Lomas, A; Bath‐Hextall, F; Leonardi‐Bee, J

05-01-2012

Journal Article

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

Chen, Z; Bruin‐Weller, M; Zhang, Q; Akinlade, B; Radin, A; Eckert, L; Gadkari, A; Smith, C.H; Cork, M.J; Pirozzi, G; Thaçi, D; Reich, K; Graham, N.M.H; Hultsch, T; Shumel, B

05-01-2018

Journal Article

Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study

Sidoroff, A; Roujeau, J. C; Valeyrie-Allanore, L; Mockenhaupt, M; Kardaun, S. H; Liss, Y; Creamer, D; Chu, C. Y; Sekula, P; Naldi, L

11-01-2013

Journal Article

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

Girolomoni, G; Crowley, J; Day, R.M; Poulin, Y; Mrowietz, U; Hu, C; Gooderham, M; Gottlieb, A.B; Ferrandiz, C; Paul, C; Cather, J; Stevens, R.M; Shah, K

12-01-2015

Journal Article

The global burden of melanoma: Results from the Global Burden of Disease Study 2015

Dellavalle, Robert P; Naghavi, Morteza; Weinstock, M.A; Nijsten, Tamar; Karimkhani, Chante; Fitzmaurice, C; Green, A

07-01-2017

Journal Article

Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis

Ottosen, M.B; Bryld, L.E; Skov, L; Dam, T.N; Rasmussen, M.K; Gniadecki, R; Broesby‐Olsen, S; Egeberg, A

02-01-2018

Journal Article

Secukinumab administration by pre‐filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

Blauvelt, A; Papavassilis, C; Gottlieb, A.B; Sofen, H; Cooper, S; Kingo, K; Ruer‐Mulard, M; Pathan, R; Prinz, J.C; Singh, V

02-01-2015

Journal Article

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017

Venning, V. A; Cruickshank, M; Samarasekera, E.J; Peleva, E; Pottinger, E; Bale, T; Mohd Mustapa, M.F; Owen, C.M; Warren, R.B; Jabbar‐Lopez, Z.K; Burden, A.D; Exton, L.S; Smith, C.H; Murphy, R; Yiu, Z.Z; Coates, L.C; Parslew, R; Nelson‐Piercy, C; Hadoke, T; Stoddart, J; Strudwicke, C; MacMahon, E

09-01-2017

Journal Article

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial

Tsai, T.‐F; Langley, R.G; Randazzo, B; Jiang, J; Wasfi, Y; Puig, L; Flavin, S; Song, M; Li, S

01-01-2018

Journal Article

No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate‐to‐severe plaque psoriasis

Porter, B; Strober, B.E; Papavassilis, C; Magid, M; Fox, T; Safi, J; Menter, A; Langley, R.G.B

02-01-2018

Journal Article

Epidemiology of acne vulgaris

Bhate, K; Williams, H.C

03-01-2013

Journal Article

Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial

Riedl, E; Langley, R.G; Shames, R; Mehta, A; Bowman, E.P; Zhou, Y; Papp, K; Krueger, J.G; Gottlieb, A.B; Nakagawa, H; Thaçi, D; Reich, K; Li, Q

10-01-2015

Journal Article

SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

Santonja, C; Rodríguez‐Peralto, J.L; Torrelo, A; Andina, D; Colmenero, I; Hernández‐Martín, A; Wiesner, T; Alonso‐Riaño, M; Noguera‐Morel, L; Requena, L

10-01-2020

Journal Article

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo‐controlled, phase III trials

Thaci, D; Abe, M; Menter, M.A; Luger, T; Wolk, R; Elewski, B; Proulx, J; Papp, K.A; Feldman, S.R; Gottlieb, A.B; Gupta, P; Langley, R; Buonanno, M; Lan, S

10-01-2015

Journal Article

Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin‐17 inhibitors and their practical management

Mrowietz, U; Puig, L; Zachariae, C; Saunte, D.M

07-01-2017

Journal Article

Comparison of long‐term drug survival and safety of biologic agents in patients with psoriasis vulgaris

Bang, B; Gniadecki, R; Lasthein, S; Bryld, L.E; Iversen, L; Skov, L

01-01-2015

Journal Article

Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta‐analysis

Totté, J.E.E; Hennekam, M; Belkum, A; Zuuren, E.J; Pasmans, S.G.M.A; Feltz, W.T

10-01-2016

Journal Article

Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up

Papp, K.A; Ghislain, P.D; Ho, V; Szapary, P.O; Wasfi, Y; Strober, B; Gordon, K; Reich, K; Griffiths, C.E.M; Chan, D; Hsu, M.‐C; Lebwohl, M

04-01-2013

Journal Article